ANGO

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.

AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.03 per share a year ago.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and full year of fiscal year 2026 before the market open on Tuesday, July 14, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the re.

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

AngioDynamics' FDA IDE approval for RELIEF advances NanoKnife IRE study as a potential minimally invasive BPH treatment.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application to initiate the RELIEF study. RELIEF is a feasibility study evaluating irreversible electroporation (IRE), the non-.